First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo;European Journal of Medicinal Chemistry;e112903;2020.10.09

Publisher：Dates：2020-10-09Views：

First orally bioavailable prodrug of proteolysis targeting chimera  (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo;European Journal of Medicinal Chemistry;e112903;2020.10.09